跳至主要内容
临床试验/CTRI/2025/08/093630
CTRI/2025/08/093630尚未招募不适用

Multivisceral Oncological Resections Involving the Pancreas An International Multicenter Study MORIP AIMS

UNIVERSITY HOSPITAL HALLE1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2025年9月30日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
1,000
试验地点
1
主要终点
Determine factors associated with morbidity, mortality, overall survival and diseasefree survival.

研究概览

简要总结

This retrospective multicenter study involves centers on a global scale performing multivisceral oncological resections involving the pancreas A retrospective analysis conducted across multiple international centers will serve to achieve the aforementioned objectives In accordance with the local standards of participating centers individual patient consent processes may be pursued for study recruitment  Some centers may have ethical or legal requirements that necessitate obtaining patient consent This approach allows for flexibility to accommodate centers where patient consent is mandatory ensuring their participation in the study However it should be noted that in centers where patient consent is not required by local standards and where there are no interventions or deviations from established treatment protocols the default approach will be to share only anonymized data This flexibility acknowledges the diversity of regulations and ethical considerations across different nations and institutions enabling the study to proceed while respecting local requirements

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • Consecutive patients undergoing elective multivisceral oncological resections involving the pancreas between January 1st 2010 and December 31st 2022 will be included.

排除标准

  • patients who underwent isolated pancreatic resection for pancreatic metastasis or revision pancreatectomies will be excluded from this analysis Patients who were not undergoing oncological resections e g traumatic lesions or those who did not undergo surgery as curative intent will be also excluded from the study Patients with incomplete data incomplete/not mentioned on EMR will be excluded from this study.

结局指标

主要结局

Determine factors associated with morbidity, mortality, overall survival and diseasefree survival.

时间窗: For overall and diseases free survival timepoint is 5 years and for mobidity and motality timepoint is 90 days after the surgery.

次要结局

  • Disease-Free Survival (DFS) / Recurrence-Free Survival – Based on recurrence data.
  • Morbidity and Mortality Rates Including 90 day mortality and postoperative complications classified by Clavien-Dindo.
  • Postoperative Specific Complications(90 days after the surgery)

研究者

发起方
UNIVERSITY HOSPITAL HALLE
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Dr Shailesh Shrikhande

TATA MEMORIAL HOSPITAL

研究点 (1)

Loading locations...

相似试验